Cargando…
Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071750/ https://www.ncbi.nlm.nih.gov/pubmed/37013621 http://dx.doi.org/10.1186/s13054-023-04419-4 |
| _version_ | 1785019257485000704 |
|---|---|
| author | Ymeraj, Senada Attou, Rachid Redant, Sebastien |
| author_facet | Ymeraj, Senada Attou, Rachid Redant, Sebastien |
| author_sort | Ymeraj, Senada |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10071750 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100717502023-04-05 Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered Ymeraj, Senada Attou, Rachid Redant, Sebastien Crit Care Correspondence BioMed Central 2023-04-03 /pmc/articles/PMC10071750/ /pubmed/37013621 http://dx.doi.org/10.1186/s13054-023-04419-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correspondence Ymeraj, Senada Attou, Rachid Redant, Sebastien Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title | Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title_full | Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title_fullStr | Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title_full_unstemmed | Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title_short | Right ventricule-specific therapies in ARDS: other vasodilating agents to be considered |
| title_sort | right ventricule-specific therapies in ards: other vasodilating agents to be considered |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071750/ https://www.ncbi.nlm.nih.gov/pubmed/37013621 http://dx.doi.org/10.1186/s13054-023-04419-4 |
| work_keys_str_mv | AT ymerajsenada rightventriculespecifictherapiesinardsothervasodilatingagentstobeconsidered AT attourachid rightventriculespecifictherapiesinardsothervasodilatingagentstobeconsidered AT redantsebastien rightventriculespecifictherapiesinardsothervasodilatingagentstobeconsidered |